ELI WHITNEY INVESTMENT COMMITTEE

of Connecticut Innovations, Incorporated

Minutes – Regular Meeting

Thursday, August 6, 2020

A regular meeting of the **Eli Whitney Investment Committee of Connecticut Innovations, Incorporated** (the “Investment Committee”) was held telephonically on August 6, 2020.

**1. Call to Order**:

Rafael Santiago, Chairperson, of the Investment Committee, noting the presence of a quorum, called the Eli Whitney Investment Committee meeting to order at 10:11 a.m. Other Investment Committee members present: Richard Mulready (by phone), and Paul Pescatello (by phone).

Absent: Alex Pencu

CI Board Members Attending: Michael Cantor, Chairperson of the CI Board (by phone).

Staff attending: Matthew Bloom (by phone), Jun Chen (by phone), Craig Colson (by phone), Peter Longo (by phone), Alison Malloy (by phone), Heidi Marshall (by phone), Matthew McCooe (by phone), Mitra Miri (by phone), Pauline Murphy (by phone), Ted Murphy (by phone), Jordan Sardo (by phone), David Wurzer (by phone), and Wenping Zhou (by phone).

**2. Approval of Minutes:**

Mr. Santiago asked the Investment Committee members to consider the minutes from the July 9, 2020 regular meeting.

**Upon a motion made by Mr. Mulready, and seconded by Mr. Pescatello, the Investment Committee members voted unanimously in favor of approving the minutes from the July 9, 2020 regular meeting, as presented.**

**3. Consent Agenda:**

Mr. Santiago asked the Investment Committee members to consider the items on the consent agenda.

**Upon a motion made by Mr. Mulready, and seconded by Mr. Pescatello, the Investment Committee members voted unanimously in favor of adopting the following resolutions:**

* **Follow-on Investment Proposals:**
* **Mount Sinai Genomics, Inc. d/b/a Sema4 – Stamford, CT**
* **Splitty Company, LTD – Greenwich, CT & Rishon LeTsivon, Israel**

**4. Follow-on Investment Proposals:**

**“Mount Sinai Genomics, Inc. d/b/a Sema4 – Stamford, CT”**

**RESOLVED:**

**(1) that financing is approved by Connecticut Innovations (“CI”) for Mount Sinai Genomics, Inc. d/b/a Sema4 of Stamford, CT in an amount of up to ONE MILLION DOLLARS ($1,000,000) for product development, sales and marketing, and working capital; and**

**(2) that Matthew McCooe, Chief Executive Officer; David Wurzer, Executive Vice President & Chief Investment Officer; Philip Siuta, Senior Vice President, Chief Financial Officer & Chief Operating Officer; or Peter Longo, Senior Managing Director, Investments, each an “Authorized Signatory”, are authorized to execute and deliver for and on behalf of CI such agreements and related documents to cause such investment to be effected, which documents shall (a) be executed by CI no later than December 31, 2020; and (b) contain such terms and conditions as the Authorized Signatory shall deem to be in the best interests of CI, including terms and conditions relating to the matters described in Section 6 of the Regulations, the Authorized Signatory’s approval thereof as hereby authorized to be conclusively evidenced by the execution and delivery of the Agreement; and**

**(3) that the Authorized Signatories hereby are severally authorized and empowered to do any and all acts and execute and deliver any and all other documents as they shall deem necessary and desirable to effectuate the above-mentioned Agreement.**

“**Splitty LTD – Greenwich, CT & Rishon LeTsivon, Israel”**

**RESOLVED:**

**(1) that financing is approved by Connecticut Innovations, Inc. (“CI”) for Splitty Company, LTD of Rishon LeTsiyon, Israel in an amount of up to THREE HUNDRED THIRTY THOUSAND DOLLARS ($330,000) for the contemplated acquisition and integration costs; and**

**(2) that Matthew McCooe, Chief Executive Officer; David Wurzer, Executive Vice President & Chief Investment Officer; Philip Siuta, Senior Vice President, Chief Financial Officer & Chief Operating Officer; or Peter Longo, Senior Managing Director, Investments, each an “Authorized Signatory”, are authorized to execute and deliver for and on behalf of CI such agreements and related documents to cause such investment to be effected, which documents shall (a) be executed by CI no later than December 31, 2020; and (b) contain such terms and conditions as the Authorized Signatory shall deem to be in the best interests of CI, including terms and conditions relating to the matters described in Section 6 of the Regulations, the Authorized Signatory’s approval thereof as hereby authorized to be conclusively evidenced by the execution and delivery of the Agreement; and**

**(3) that the Authorized Signatories hereby are severally authorized and empowered to do any and all acts and execute and deliver any and all other documents as they shall deem necessary and desirable to effectuate the above-mentioned Agreement.**

**5. Other Business:**

There was no other business to report.

**6. Date for Next Meeting:**

September 10, 2020 at 10:30 a.m.

**7. Adjournment:**

**Upon a motion made by Mr. Mulready­­, and seconded by Mr. Pescatello, the Investment Committee members voted unanimously in favor of adjourning the August 6, 2020 regular meeting at 10:15 a.m.**

Respectfully submitted,

Rafael Santiago

Chairperson of the Eli Whitney Investment Committee